{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:11:20Z","timestamp":1769271080575,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009342","name":"Aeras, Rockville, MD, USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.03.069","type":"journal-article","created":{"date-parts":[[2016,3,27]],"date-time":"2016-03-27T07:01:02Z","timestamp":1459062062000},"page":"2430-2436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON\u00ae-TB Gold (+) Kenyan adults without evidence of tuberculosis"],"prefix":"10.1016","volume":"34","author":[{"given":"Douglas S.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victorine","family":"Owira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Polhemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Andagalu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhards","family":"Ogutu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Waitumbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Hawkridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Pau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Bruce","family":"McClain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.03.069_bib0060","series-title":"Global tuberculosis report 2014","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","article-title":"The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature","volume":"96","author":"Colditz","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0070","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/IAI.00004-07","article-title":"Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon","volume":"75","author":"Radosevic","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0075","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"Abel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0080","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.vaccine.2012.01.048","article-title":"A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity","volume":"30","author":"Hoft","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0085","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected adults with CD4+ T cell counts >350cells\/mm3","volume":"33","author":"Churchyard","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0090","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8 T cell responses","volume":"32","author":"Kagina","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0095","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.vaccine.2015.03.070","article-title":"A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tluberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants","volume":"33","author":"Tameris","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0100","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"Sprangers","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0105","doi-asserted-by":"crossref","first-page":"e3790","DOI":"10.1371\/journal.pone.0003790","article-title":"rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector","volume":"3","author":"Magalhaes","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2016.03.069_bib0110","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"AIDS"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16300652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16300652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:14:05Z","timestamp":1759400045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16300652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":11,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16300652"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON\u00ae-TB Gold (+) Kenyan adults without evidence of tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}